A report of a pregnancy cardiomyopathy treated with Bromocriptin

Document Type : Case report


1 Assistant Professor, Department of Cardiology, Cardiovascular Disease Prevention Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Assistant Professor, Department of Obstetrics and Gynecology, Women's Health Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Resident of Obstetrics and Gynecology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.


Introduction: Peripartum Cordiomyopathy is a disease of unknown cause during the last trimester of pregnancy or puerperium. Considering to new treatment in addition to conventional treatments of heart failure, in this report, a case of PeriPartumperiod heart failure is introduced.
Case report: A 32 years old lady in 37th week of pregnancy referred with dyspnea NYHA Class III, and had no history of heart disease, and in examination, the lungs were clear and there was a systolic murmur III/IV in LV apex. Left Ventricular dysfunction was 25-30% with Right ventricular dysfunction. These findings were suggestive of PPCM. The patient underwent treatment of heart failure, but Exacerbated after delivery and underwent treatment with bromocriptine. After 1 year, symptoms improved and LVEF was 45-50% in re-echocardiography.
Conclusion: Bromocriptine can be effective in improvement of ventricular function of patients with heart failure.


  1. Yancy C.W, Jessup M, Bozkurt B,et al.A Report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines.2013 ACCF/AHA Guideline for the Management of Heart Failure.Journal of American College of Cardiology. Vol 62,No 16,2013.
  2. Reimold S.Rutherford.et al.Peri and Post partum Cardiomyopathy.New Eng J Med 2001.
  3. Katrin Walenta1,Viktoria Schwarz1, Stephan H, Kindermann I, Friedrich EB, Solomayer EF, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J 2012; 33(12):1469-79.
  4. Hilfiker-Kleiner D, Sruman I, Hoch M, Podewski E, Sliwa K. Melanie Hoch.et al.16kd  Prolactin and Bromocriptin in periPartum Cardiomyopathy. Curr Heart Fail Rep 2012; 9(3):174-82.
  5. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. A Proof-of Concept Pilot Study. Circulation 2010; 121(13):1465-73.
  6. Wexler BC, McMurtry JP. Hormonal and metabolic changes during acute myocardial infarction in normotensive vs hypertensive rats. Br J Ex Pathol. 1983; 64: 124–136.
  7. Leaños-Miranda A, Márquez-Acosta J, Cárdenas-Mondragón GM, Chinolla-Arellano ZL, Rivera-Leaños R, Bermejo-Huerta S, et al. Unirary Prolactin as a reliable marker for Preeclampsia,Its severity and the occurrence of adverse pregnancy outcomes. J Clinic Endoc Metabol 2008;93(7):2493-9.
  8. Chopra S, Verghese PP, Jacob JJ.Bromocriptine  as a new therapeutic  agent for Peripartum  Cardiomyopathy. Indian J Endocrinol Metab 2012; 16(Suppl 1):S 60-2.
  9. Ballo P, Betti I, Mangialavori G,  Chiodi  L, Rapisardi G, Zuppiroli  A, et al. Peripartum Cardiomyopathy Presenting with Predominant Left Ventricular Diastolic Dysfunction: Efficacy of Bromocriptine. Case Rep Med  2012; 2012: 476903.
  10. Habedank D, Kühnle Y, Elgeti T, Dudenhausen JW, Haverkamp W, Dietz R. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008;  10(11):1149-51.
  11. Fett J.D. Caution in the Use of Bromocriptine in Peripartum Cardiomyopathy.Letter to Eidtor. JACC Vol. 51, No. 21, 2008 .2082–4.